Gyre Therapeutics, Inc. Costs and Expenses
Gyre Therapeutics, Inc. (GYRE) reported Costs and Expenses of $43.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-07
- Gyre Therapeutics, Inc. costs and expenses for the quarter ending 2026-06-30 was $43.47M, a 35.95% increase year-over-year.
- Gyre Therapeutics, Inc. costs and expenses for the quarter ending 2026-03-31 was $31.87M, a 61.10% increase year-over-year.
- Gyre Therapeutics, Inc. costs and expenses for the quarter ending 2025-12-31 was $37.08M, a 36.28% increase year-over-year.
- Gyre Therapeutics, Inc. costs and expenses for the quarter ending 2025-09-30 was $23.64M, a 11.22% increase year-over-year.
- Gyre Therapeutics, Inc. costs and expenses for fiscal 2025 was $105.10M, a 17.31% increase from fiscal 2024.
- Gyre Therapeutics, Inc. costs and expenses for fiscal 2024 was $89.59M, a 50.41% decline from fiscal 2023.
- Gyre Therapeutics, Inc. costs and expenses for fiscal 2023 was $180.68M, a 94.10% increase from fiscal 2022.
- Gyre Therapeutics, Inc. costs and expenses for fiscal 2022 was $93.09M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 3 month as first filed | Costs and Expenses 6 month | Costs and Expenses 6 month as first filed | Costs and Expenses 9 month | Costs and Expenses 9 month as first filed | Costs and Expenses 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $43.47M 10-Q · filed 2026-08-07 | $86.87M 10-Q · filed 2026-08-07 | $112.42M derived: sum of 3 quarters · filed 2026-08-07 | $136.06M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2026-03-31 | $31.87M 10-Q · filed 2026-05-08 | $68.95M derived: sum of 2 quarters · filed 2026-05-08 | $92.59M derived: sum of 3 quarters · filed 2026-05-08 | $124.56M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-12-31 | $37.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $60.72M derived: sum of 2 quarters · filed 2026-03-13 | $92.69M derived: sum of 3 quarters · filed 2026-08-07 | $105.10M 10-K · filed 2026-03-13 | |||
| 2025-09-30 | $23.64M 10-Q · filed 2025-11-07 | $55.61M derived: sum of 2 quarters · filed 2026-08-07 | $68.02M 10-Q · filed 2025-11-07 | $102.61M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-06-30 | $31.97M 10-Q · filed 2026-08-07 | $24.60M 10-Q · filed 2025-08-11 | $60.00M 10-Q · filed 2026-08-07 | $44.38M 10-Q · filed 2025-08-11 | $78.97M derived: sum of 3 quarters · filed 2026-08-07 | $100.22M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | $19.79M 10-Q · filed 2026-05-08 | $46.99M derived: sum of 2 quarters · filed 2026-05-08 | $68.25M derived: sum of 3 quarters · filed 2026-05-08 | $90.28M derived: sum of 4 quarters · filed 2026-05-08 | |||
| 2024-12-31 | $27.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $48.46M derived: sum of 2 quarters · filed 2026-03-13 | $70.49M derived: sum of 3 quarters · filed 2026-03-13 | $89.59M 10-K · filed 2026-03-13 | |||
| 2024-09-30 | $21.25M 10-Q · filed 2025-11-07 | $43.29M derived: sum of 2 quarters · filed 2025-11-07 | $62.39M 10-Q · filed 2025-11-07 | $62.32M 10-Q · filed 2024-11-13 | $181.17M derived: sum of 4 quarters · filed 2025-11-07 | ||
| 2024-06-30 | $22.03M 10-Q · filed 2025-08-11 | $21.96M 10-Q · filed 2024-08-13 | $41.13M 10-Q · filed 2025-08-11 | $41.06M 10-Q · filed 2024-08-13 | $159.91M derived: sum of 3 quarters · filed 2025-08-11 | $179.19M derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | $19.10M 10-Q · filed 2025-05-09 | $137.88M derived: sum of 2 quarters · filed 2025-05-09 | $157.16M derived: sum of 3 quarters · filed 2025-05-09 | $181.51M derived: sum of 4 quarters · filed 2025-05-09 | |||
| 2023-12-31 | $118.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $138.06M derived: sum of 2 quarters · filed 2025-03-17 | $162.41M derived: sum of 3 quarters · filed 2025-03-17 | $180.68M 10-K · filed 2025-03-17 | |||
| 2023-09-30 | $19.28M 10-Q · filed 2024-11-13 | $43.63M derived: sum of 2 quarters · filed 2024-11-13 | $61.90M 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | $24.36M 10-Q · filed 2024-08-13 | $42.62M 10-Q · filed 2024-08-13 | |||||
| 2023-03-31 | $18.27M 10-Q · filed 2024-05-13 | ||||||
| 2022-12-31 | $93.09M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |